The identification of three cases with germline BRCA1 mutations with somatic SHLD2 mutations in post-PARPi tumour samples suggests that through loss of the Shieldin complex, cells are diverted from NHEJ, restoring homologous recombination, leading to resistance. Here, SHLD2 is linked to neoplasm.